| 2.03 0.01 (0.5%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.8 | 1-year : | 3.13 |
| Resists | First : | 2.4 | Second : | 2.68 |
| Pivot price | 2.21 |
|||
| Supports | First : | 1.95 | Second : | 1.62 |
| MAs | MA(5) : | 2.05 | MA(20) : | 2.29 |
| MA(100) : | 2.67 |
MA(250) : | 2.81 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12 |
D(3) : | 14.2 |
| RSI | RSI(14): 36.8  |
|||
| 52-week | High : | 4.34 | Low : | 1.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABCL ] has closed above bottom band by 30.4%. Bollinger Bands are 27.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.06 - 2.07 | 2.07 - 2.08 |
| Low: | 1.98 - 1.99 | 1.99 - 2 |
| Close: | 2.01 - 2.03 | 2.03 - 2.05 |
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Fri, 16 May 2025
Truist Securities Lowers Price Target for AbCellera Biologics (ABCL) | ABCL Stock News - GuruFocus
Fri, 16 May 2025
Truist Adjusts Price Target for AbCellera (ABCL) Amid Strategic Shift | ABCL Stock News - GuruFocus
Thu, 15 May 2025
Abcellera gains Canadian clearance for phase I study of ABCL-635 for vasomotor symptoms in menopause - BioWorld MedTech
Thu, 15 May 2025
Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates - simplywall.st
Mon, 12 May 2025
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 298 (M) |
| Shares Float | 203 (M) |
| Held by Insiders | 22.8 (%) |
| Held by Institutions | 41.5 (%) |
| Shares Short | 23,780 (K) |
| Shares Short P.Month | 22,790 (K) |
| EPS | -0.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.56 |
| Profit Margin | 0 % |
| Operating Margin | -807.1 % |
| Return on Assets (ttm) | -12.5 % |
| Return on Equity (ttm) | -14.8 % |
| Qtrly Rev. Growth | -45 % |
| Gross Profit (p.s.) | -0.47 |
| Sales Per Share | 0.09 |
| EBITDA (p.s.) | -0.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -109 (M) |
| Levered Free Cash Flow | -178 (M) |
| PE Ratio | -3.7 |
| PEG Ratio | 0 |
| Price to Book value | 0.56 |
| Price to Sales | 21.01 |
| Price to Cash Flow | -5.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|